CD28
Constitutive: mouse (all T cells), human (95% of CD4 + , 50% of CD8 + T cells), plasma cells, NK cells Stimulation of naive and previously activated T cells upon TCR ligation: ↑ proliferation (↓ p27 Kip1 , ↑ G 1 /S); ↑ cytokine production (↑ NFκB, ↑ IL2); ↑ survival (↑ Bcl-x L , ↑ survival of Tregs); ↑ glucose metabolism; provides T cell-dependent B cell help for class switching.
Blockade of pathway to treat autoimmune infl ammatory diseases and for transplantation; active engagement to expand anti-tumor T cells and Tregs
B7-2 (CD86)
Constitutive at low levels; inducible: APCs, T cells
B7-1
Inducible: APCs (slower kinetics than B7-2), T cells CTLA-4 (CD152) Inducible: T cells; constitutive: Tregs Inhibition of TCR-dependent activation: ↓ proliferation (↑ p27 Kip1 , ↓ G 1 /S); ↓ cytokine production (↓ NFκB, ↓ IL2); CD28-dependent and -independent functions; promotes inhibitory function of Tregs.
Blockade of pathway in tumor immunotherapy; receptor polymorphisms linked with autoimmunity
B7-2
Constitutive at low levels; inducible: APCs, T cells Icosl (B7h, B7-H2, CD275, LICOS, B7RP-1)
Induced by TNFα and IFNγ: APCs, T cells, fi broblasts, endothelium ICOS (CD278) Inducible: T cells (CD28-dependent and CD28-independent); constitutive: resting memory T cells, Tregs Stimulation: ↑ proliferation (modest compared to CD28); ↑ cytokine production by effector T cells (IL4 > IFNγ); ↑ survival (↑ Bcl-x L , ↑ IL23-mediated survival of Th17); ↑ GC formation and isotype class switching. Inhibition: ↑ IL10 cytokine production.
Receptor polymorphisms associated with immunodefi ciency and autoimmunity Table: Binding Partners in the B7/CD28 Family of Costimulatory Molecules T cells require two signals for optimal activation. The first signal is delivered to the T cell receptor (TCR) by processed antigen displayed by major histocompatibility complex (MHC) molecules; this antigen-dependent signal provides specificity to the immune response. The second signal, known as the costimulatory signal, is delivered to receptors on T cells by costimulatory molecules. These cell-surface molecules provide contextual information that influences the ensuing immune response. Costimulatory signals can have either stimulatory or inhibitory effects on T cells. As several interactions can occur throughout the activation and effector phases of the immune response, it appears that the overall balance between positive and negative costimulation directs the magnitude, location and type of response. Temporal and spatial regulation of expression of both costimulatory receptors and ligands leads to dynamic modulation of T cell priming, homing, and effector function. Importantly, these molecules potentially can be targeted for therapy to block undesirable immune activation, for example during autoimmune disease or organ transplant rejection, or to stimulate desired immune responses to combat cancer or infection. The best described costimulatory interactions are those in the B7/CD28 family. B7 family members typically act as ligands for CD28 receptor family members, although B7-1 and PD-L1 (both B7 family members) can also act as receptors themselves. There are also crossfamily interactions, such as B7-H3 binding to the TREM receptor family member TREM-like transcript-2 (TLT-2) and BTLA binding to HVEM . HVEM also binds to LIGHT (TNF superfamily, member 14) and to lymphotoxin α to stimulate T cell responses; HVEM can also bind to CD160, an Ig superfamily member, to inhibit T cell responses. Other members of the B7/CD28 family may still await discovery, and alternative receptors for known family members may exist. For example, there are data to suggest the existence of a stimulatory receptor for PD-L1 and PD-L2. B7-H3 may also interact with a putative inhibitory receptor on T cells in addition to the stimulatory TLT-2.
A N T I G E N P R E S E N T I N G C E L L T C E L L
Figure: B7/CD28 Family Interactions and Signaling Pathways B7/CD28 family members are defined structurally by their common IgC-IgV extracellular binding domains, and signaling pathways are driven primarily by intracellular tyrosine-containing motifs. Apart from the specific antigen-dependent signal provided by the MHC-antigen complex to the TCR, the cell-surface interactions involving the B7/CD28 family of costimulatory molecules provide a second signal to T cells to enhance or inhibit the canonical TCR signaling pathway, leading to changes in T cell proliferation, survival, and cytokine production. Human B7-H3 has an extracellular domain composed of IgV-IgC-IgV-IgC, whereas the mouse form of B7-H3 (shown in the figure) consists of an IgV-IgC extracellular domain.
Abbreviations AP1, activator protein 1; APCs, antigen-presenting cells; B7-H, B7 homolog; BTLA, B and T lymphocyte attenuator; BTNL2, butyrophilin-like 2; CTL, cytotoxic T lymphocyte; CTLA-4, cytotoxic T lymphocyte antigen-4; DCs, dendritic cells; EAE, experimental autoimmune encephalomyelitis; GC, germinal center; GVHD, graft-versus-host disease; HVEM, herpesvirus entry mediator; ICOS, inducible costimulator; ICOSL, ICOS ligand; IFN, interferon; Ig, immunoglobulin; IL, interleukin; LIGHT, homologous to lymphotoxins, exhibits inducible expression, and competes with herpes simplex virus glycoprotein D for HVEM, a receptor expressed by T lymphocytes; mTOR, mammalian target of rapamycin; NFAT, nuclear factor of activated T cells; NFκB, nuclear factor kappa B; NK, natural killer; PD-1, programmed death-1; PD-L, programmed death-1 ligand; PI3K, phosphatidylinositol 3 kinase; PLC, phospholipase C; Th17, IL17-producing helper T cell; TNF, tumor necrosis factor; TNFR, TNF receptor; Tregs, regulatory T cells; TREM, triggering receptor expressed on myeloid cells; ZAP70, zeta-associated protein kinase 70.
